Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail shows promise for lymphoma patients

NCT ID NCT01829568

First seen Jan 05, 2026 · Last updated May 19, 2026 · Updated 26 times

Summary

This early-stage study tested a combination of three drugs (rituximab, lenalidomide, and ibrutinib) in 33 people with untreated follicular lymphoma, a slow-growing blood cancer. The main goal was to find the safest doses and identify side effects. While the drugs aim to control the disease, patients may need ongoing treatment, so this is not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE III GRADE 1 FOLLICULAR LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia, 20007, United States

  • NYP/Weill Cornell Medical Center

    New York, New York, 10065, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, 27599, United States

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, 60637, United States

Conditions

Explore the condition pages connected to this study.